The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for mesothelin targeting Recombinant Immunotoxins (RITs). These RITs have been engineered by site specific modification with polyethylene glycol (PEG) to have an increased serum half-life, while maintaining high cytotoxicity and have greatly improved anti-tumor activity.
Inventors at the National Cancer Institute (NCI) have developed chimeric antigen receptors (CARs) that target two B cell surface antigens, CD19 and CD22, improving treatment of B-cell malignancies, such as acute lymphoblastic leukemia (ALL). NCI is actively seeking parties interested in licensing this invention to commercialize the bicistronic CAR construct targeting CD19 and CD22 for immunotherapy.
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for further development of novel iodonium analogs. These iodonium analogs inhibit NADPH oxidases (NOX) and other flavin dehydrogenases to slow tumor growth.
Scientists at the National Cancer Institute (NCI) have developed a novel delivery platform in which the scaffold of an anionic hydrogel (AcVES3) can be attenuated to deliver therapeutic small molecules, peptides, proteins, nanoparticles, or whole cells. The NCI seeks collaborators and licensees for the development of this technology in various clinical and laboratory applications.
Scientists at the National Cancer Institute (NCI) discovered that the cyclic peptide recifin inhibits the activity of tyrosyl-DNA phosphodiesterase 1 (TDP1), a molecular target for the sensitization of cancer cells to the topoisomerase 1 (TOP1) inhibitor camptothecin and its chemotherapeutic derivatives – such as topotecan and irinotecan. NCI seeks research co-development partners and/or licensees for the development of recifin and its analogues as new chemosensitizing agents in adjunct therapies to enhance the sensitivity of cancer cells to topotecan, irinotecan and related chemotherapeutic agents.
Pluripotent stem cells are a promising source of T cells for a variety of clinical applications. However, current in vitro methods of T cell differentiation result in the generation of cells with aberrant phenotypes. Researchers at the National Cancer Institute (NCI) have now developed methodology for generating induced pluripotent stem cell thymic emigrants (iTE). Antigen-specific CD8αβ+ iTEs exhibited functional properties in vitro that were almost indistinguishable from natural naïve CD8αβ+ T cells, including vigorous expansion and robust anti-tumor activity. iTEs recapitulated many of the transcriptional programs of naïve T cells in vivo and revealed a striking capacity for engraftment, memory formation, and efficient tumor destruction. The NCI seeks licensing and/or co-development research collaborations for this invention.
Researchers at the National Cancer Institute (NCI) have discovered a small molecule that binds to CD206 and activates M2-like tumor associated macrophages resulting in innate and adaptive anti-tumor responses. NCI seeks research co-development or licensees for CD206 small molecule modulators as a therapeutic for CD206-expressing cancers (such as pancreatic, sarcoma, head and neck, lung, gastric, triple negative breast, renal cell, colorectal cancer, melanoma).
The National Cancer Institute (NCI) seeks licensees for a method of high-throughput generation of induced pluripotent stem cells carrying antigen-specific T cell receptors from tumor infiltrated lymphocytes.
Researchers at the National Cancer Institute (NCI) have isolated seven monoclonal antibodies that bind to the human epidermal growth factor receptor variant III (EGFRvIII) but not wildtype EGFR. The NCI seeks research co-development partners or licensees for monoclonal antibodies that specifically target cancer-expressed EGFR.
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for the development and commercialization of small molecule inhibitors of the Eph receptor tyrosine kinase for Eph growth-dependent solid tumors such as colorectal cancer.
The National Cancer Institute (NCI) seeks licensees for a collection of T-cell receptors (TCRs) that specifically target the CD20 antigen expressed in B-lymphoid malignancies such as non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia, and acute lymphoblastic leukemia. The TCRs are being developed as therapeutics for the treatment of lymphomas and leukemias.
Increased cyclin-dependent kinase 5 (CDK5) activity has recently emerged as a contributor to cancer progression. Researchers at the National Cancer Institute (NCI) and at the National Institute of Neurological Disorders and Stroke (NINDS) have shown that TP5, a small peptide inhibitor of CDK5 modified to facilitate passage through the blood brain barrier (BBB), has potential therapeutic benefit in glioblastoma (GBM) and colorectal carcinoma (CRC). NCI is seeking parties interested in co-developing and/or licensing TP5 for its use in the treatment of cancers with aberrant CDK5 expression as a mono-therapy or in an adjuvant setting with current standard-of-care.
Researchers at the National Cancer Institute (NCI) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) have developed novel heterocyclic scaffold-based inhibitors of the polo-box domain (PBD) of Polo-like kinase 1 (Plk1). These compounds effectively arrest mitotic progression and cell proliferation in cell-based assays. The National Institutes of Health (NIH) seeks licensing and/or co-development research collaborations to further develop these inhibitors for the treatment of cancer.
The National Cancer Institute (NCI) seeks licensees for a collection of novel T-cell receptors (TCRs) that target the Epstein Barr Virus Latent Membrane Protein 2 (EBV-LMP2). The TCRs are being developed as therapeutics for treatment of lymphomas and epithelial cancers.
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a method of direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing.
Investigators at the National Cancer Institute (NCI) seek co-development partners and/or licensees for a new therapeutic approach that selectively targets cancer cells and prevents tumor regrowth. The novel method combines antibody-IR700 molecules and Near-Infrared Photo Immunotherapy (NIR-PIT), which has shown great potential in targeting tumors via a host immunogenic response, with already known and available anti-cancer immunomodulators to further enhance the antitumor response. The investigators have shown in mouse models that, when used in combination, NIR-PIT-treatment and standard antitumor agents conferred a potent vaccine-like effect, not only curing mice of local and distant cancers but successfully immunizing them against tumor regrowth.
Inventors at the National Cancer Institute (NCI) developed novel recombinant immunotoxins (RITs) with a long half-life due to added albumin binding domains (ABD) and high anti-tumor activity. This technology is available for research co-development partnering or licensing.
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a method to identify T cells with preferred phenotypes for increased response from adoptive immunotherapy.